Sign In
Buy TAK
$16.49
-0.0700 (-0.423%)
At Close: Jul 13, 2026
OSAKA, Japan & CAMBRIDGE, Mass. & JAKARTA, Indonesia--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and the Indonesian Government (the Ministry of Health, the Ministry of Investment and Downstream Indus
Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery
10:16pm, Wednesday, 01'st Jul 2026
Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leade
Takeda, InSilico Strike AI Drug-Discovery Deal Worth Up to $600 Million
07:59pm, Wednesday, 01'st Jul 2026
Takeda is set to pay InSilico to use its proprietary Pharma. AI platform to advance drug candidates across several therapeutic areas, according to people familiar with the matter.
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
07:45am, Tuesday, 30'th Jun 2026
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
03:05am, Wednesday, 24'th Jun 2026
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--In the final step of its 18-month CEO transition, Takeda (TOKYO:4502/NYSE:TAK) today announced that Julie Kim was officially appointed Takeda's Repres
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin r
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
07:03am, Thursday, 11'th Jun 2026
Japan's Takeda Pharmaceutical said on Thursday its experimental once-daily psoriasis pill, developed with the help of AI, outperformed Bristol Myers Squibb's approved drug Sotyktu in a late-stage h
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
04:30pm, Tuesday, 09'th Jun 2026
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Appl
Takeda Pharmaceutical Co Ltd (TAK) Shares Fall 4.8% -- GF Value Says Still Overvalued
06:23pm, Monday, 01'st Jun 2026
On June 01, 2026, Takeda Pharmaceutical Co Ltd (TAK) shares fell 4.8% to $15.19. The stock has faced a decline over the past month, with a 1-week drop of 6.5% a
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
01:15pm, Friday, 22'nd May 2026
DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
05:51pm, Monday, 18'th May 2026
BOSTON--(BUSINESS WIRE)---- $TAK #antitrust--A class-action lawsuit regarding Amitiza ended today when a jury found Takeda Pharmaceuticals liable for $474 million, according to Hagens Berman.
Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds
02:53pm, Monday, 18'th May 2026
A U.S. jury on Monday found that Takeda Pharmaceutical caused pharmacies, insurers, retailers and others to sustain about $885 million in damages delaying the release
Takeda's Rich Pipeline Optionality Is Worth A 'Buy'
06:29am, Monday, 18'th May 2026
TAK's FY2025 revenue was about $28.4 billion, which was down 1.7% YoY due to Vyvanse's generic pressure. This remains a growth headwind until their first wave launches. Management is pairing a new tra
Takeda Pharmaceutical Q4 Earnings Call Highlights
08:13am, Friday, 15'th May 2026
Takeda Pharmaceutical NYSE: TAK reported fiscal 2025 results that management described as solid despite pressure from generic competition to VYVANSE, while outlining a transition plan built around thr
